Tumor size and prognosis in aggressively treated osteosarcoma.

PURPOSE The aim of this retrospective analysis was to investigate the prognostic significance and optimal measures of tumor size in osteosarcoma treated with intensive neoadjuvant chemotherapy. PATIENTS AND METHODS Initial anterior-posterior (AP) and lateral x-ray films of 128 patients treated within the trials Cooperative Osteosarcoma Study (COSS)-80, -82, and -86, were evaluated for the following three tumor diameters: length, width, and depth. Metastasis-free survival (MFS) analyses were performed in univariate and multivariate models with one, two, and three dimensions of the tumor as absolute or relative measures (tumor length, referred to bone length, plane and volume to body-surface area). RESULTS Univariate analyses of MFS showed a high prognostic significance of all absolute measures. Relative measures, at best, showed a comparable predictive value. Cox regression analysis indicated the high prognostic significance of absolute tumor volume (ATV; P < .0001) and histologic response (P < .0001). None of 19 patients with an ATV < or = 70 cm3 and only four of 53 with an ATV < or = 150 cm3 relapsed, while in patients with an ATV more than 150 cm3, the relapse rate remained 40% to 60%, irrespective of further increase in volume. CONCLUSION Initial tumor size is an important and easily obtainable prognostic factor in osteosarcoma and may serve as a basis for risk-adapted therapy. It is best represented by the absolute three-dimensional measure ATV. There is a cut-off point regarding the incidence of metastases at a tumor volume of approximately 150 cm3 as calculated from two-plane x-ray films.

[1]  W. Taylor,et al.  A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E L Kaplan NON-PARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATION , 1958 .

[3]  S. Leyvraz,et al.  Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high‐dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS‐86) , 1990, Cancer.

[4]  W. Taylor,et al.  Prognostic variables in osteosarcoma: a multi-institutional study. , 1989, Journal of the National Cancer Institute.

[5]  A. Davis,et al.  Prognostic factors in osteosarcoma: a critical review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Taylor,et al.  Trends and variability in survival among patients with osteosarcoma: a 7-year update. , 1985, Mayo Clinic proceedings.

[7]  M. Marangolo,et al.  Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities. , 1991, Clinical orthopaedics and related research.

[8]  H. Mouridsen,et al.  Prognostic factors in osteosarcomas. A regression analysis , 1988, Cancer.

[9]  W. Ebell,et al.  Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Fuchs,et al.  Die prognostische Bedeutung des Tumorvolumens beim Osteosarkom unter neoadjuvanter Chemotherapie , 1993 .

[11]  G Uribe-Botero,et al.  Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. , 1977, American journal of clinical pathology.

[12]  M. van Glabbeke,et al.  Osteosarcoma of the limbs. Report of the EORTC‐SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation , 1988, Cancer.

[13]  A. Giuliano,et al.  Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Rosen,et al.  Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience , 1992, Cancer.

[15]  H. Jürgens,et al.  Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Strander,et al.  Survival in osteosarcoma in relation to tumor size and location. , 1982, Clinical orthopaedics and related research.

[17]  A. Craft,et al.  A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Jaffe,et al.  Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Shuster,et al.  The effect of local extent of the tumor on prognosis in osteosarcoma. , 1990, The Journal of bone and joint surgery. American volume.

[20]  M. Weiner,et al.  Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. , 1986, Cancer treatment reports.

[21]  N. Jaffe,et al.  Intraarterial cisplatin in the management of stage IIB osteosarcoma in the pediatric and adolescent age group. , 1991, Clinical Orthopaedics and Related Research.

[22]  S. Bielack,et al.  Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. , 1991, Clinical orthopaedics and related research.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  N. Jaffe,et al.  Increased survival, limb preservation, and prognostic factors for osteosarcoma , 1991, Cancer.

[25]  G Rosen,et al.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[27]  P. Picci,et al.  Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities the istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin , 1990, Cancer.

[28]  P. Scranton,et al.  Prognostic factors in osteosarcoma: A review of 20 years' experience at the university of pittsburgh health center hospitals , 1975 .

[29]  P. Picci,et al.  Neoadjuvant chemotherapy for osteosarcoma of the extremity. , 1987, Clinical orthopaedics and related research.